linerixibat

News

Alfasigma claims early FDA nod for ex-GSK liver drug

Alfasigma has claimed the first approval, in the US, for linerixibat, a drug for liver disease PBC licensed from GSK for $690m a few days ago.

News

Alfasigma licenses liver drug from GSK in $690m deal

With an FDA verdict looming, GSK has signed an eleventh-hour deal to give Alfasigma rights to its primary biliary cholangitis therapy linerixibat.

News

EU kicks off review of GSK's linerixibat in PBC

GSK's drug for severe itching in patients with autoimmune liver disease PBC is now under review in the EU and US, as Mirum Pharma tries to catch up.

News

GSK reveals data behind linerixibat for PBC 'relentless itch...

GSK reveals the data behind its linerixibat for itching associated with autoimmune liver disease PBC as it anticipates first approvals for the drug.

News

GSK drug raises hopes for patients with PBC itch

GSK has reported promising results with a drug to treat the severe itching that plagues patients with rare cholestatic liver disease primary biliary cholangitis (PBC).

Alfasigma claims early FDA nod for ex-GSK liver drug

Alfasigma licenses liver drug from GSK in $690m deal

EU kicks off review of GSK's linerixibat in PBC

GSK reveals data behind linerixibat for PBC 'relentless itch...

GSK drug raises hopes for patients with PBC itch

Hernexeos and what’s next, with Vicky Brown

Using AI-driven synthetic personas to take your insights fur...

linerixibat

Editor's Picks